Table 1.
Characteristics of the treated population.
| Variable | n | % |
|---|---|---|
| No. of patients | 24 | 100 |
| Age (median, IQR range) | 52 (41–60) | |
| ECOG 1 | ||
| 0 | 6 | 25 |
| 1 | 14 | 58 |
| 2 | 4 | 17 |
| CDK4/6i | ||
| Ribociclib | 16 | 67 |
| Palbociclib | 6 | 25 |
| Abemaciclib | 2 | 8 |
| Endocrine therapy | ||
| Letrozole | 15 | 62 |
| Fulvestrant | 9 | 38 |
| De novo disease | 6 | 25 |
| Previous CHT | 18 | 75 |
| Previous CHT < 1y 2 | 6 | 25 |
| RT in relation to CDK4/6i | ||
| Before starting CDK4/6i | 11 | 46 |
| Concurrent with CDK4/6i | 6 | 25 |
| After CDK4/6i completion | 7 | 29 |
1 ECOG—Performance status assessed by Eastern Cooperative Oncology Group; 2 CHT < 1y—chemotherapy within one year before CDK4/6i treatment.